Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 5/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641453 | 0.92 | TYK2 (0.53) | TYK2STAT3TAS2R14CSNK2A2CSNK2A1 | |
| SCHEMBL3313699 | 0.92 | TYK2 (0.55) | TYK2STAT3TAS2R14CSNK2A2CSNK2A1 | |
| SCHEMBL3315693 | 0.90 | TYK2 (0.55) | TYK2STAT3TAS2R14CSNK2A2CSNK2A1 | |
| SCHEMBL2309014 | 0.89 | TYK2 (0.51) | TYK2STAT3TAS2R14CSNK2A2CSNK2A1 | |
| SCHEMBL2309382 | 0.86 | TYK2 (0.56) | TYK2STAT3TAS2R14CSNK2A2CSNK2A1 | |
| SCHEMBL3313759 | 0.85 | TYK2 (0.49) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL3313533 | 0.84 | TYK2 (0.54) | TYK2STAT3TAS2R14PDE4D | |
| SCHEMBL2356721 | 0.84 | TYK2 (0.54) | TYK2STAT3TAS2R14CSNK2A2CSNK2A1 | |
| SCHEMBL3311204 | 0.83 | TYK2 (0.75) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL3313726 | 0.82 | TYK2 (0.54) | TYK2STAT3TAS2R14CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252795-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | TYK2 393/4885STAT3 764/4885TAS2R14 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.